SCHEMBL619731

SCHEMBL619731

CCCCCCC(CCCCCCCCCCCC(=O)O)(CCCCCCCCCC(=O)O)C(=O)OCC(O)CO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
KDM4E B2RXH2 1/20 0.58
DUSP3 P51452 1/20 0.58
LMNA P02545 1/20 0.58
DGKA P23743 1/20 0.51
FFAR4 Q5NUL3 2/20 0.49
FFAR1 O14842 2/20 0.49
GPR84 Q9NQS5 7/20 0.46
PPARG P37231 7/20 0.46
PPARD Q03181 7/20 0.46
PPARA Q07869 7/20 0.46
HDAC11 Q96DB2 5/20 0.46
TSHR P16473 4/20 0.46
PTPN1 P18031 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adipic Acid SCHEMBL2338266 0.92 MEN1 (0.52) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL28712011 0.92 MEN1 (0.59) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL4966666 0.92 MEN1 (0.59) MEN1KMT2AKDM4EDUSP3LMNA
Adipic Acid SCHEMBL2192313 0.91 KDM4E (0.62) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL6836331 0.86 FFAR1 (0.66) KMT2ADUSP3LMNADGKAFFAR4
SCHEMBL28830667 0.86 KDM4E (0.56) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL7574622 0.84 DGKA (0.65) MEN1KMT2AKDM4EDUSP3LMNA
Dodecanoate SCHEMBL27989755 0.83 MEN1 (0.69) MEN1KMT2AKDM4EDUSP3LMNA
Dodecanoate SCHEMBL28287632 0.83 MEN1 (0.69) MEN1KMT2AKDM4EDUSP3LMNA
Octanoic Acid SCHEMBL9928775 0.83 MEN1 (0.69) MEN1KMT2AKDM4EDUSP3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024134493-A1 DRUG DELIVERY SYSTEM FOR TIRZEPATIDE QUISITIVE THERAPEUTICS (IN) 2024-06-27 WO disclosed
US-11173210-B2 Temperature-responsive degradable hydrogels SONORAN BIOSCIENCES, INC. (US) 2021-11-16 US disclosed
US-20210252156-A1 METHODS OF TREATING NAUSEA UTILIZING SEMI-SOLID DELIVERY VEHICLE COMPOSITIONS COMPRISING GRANISETRON HERON THERAPEUTICS INC (US) 2021-08-19 US disclosed
EP-3834817-A1 SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS Heron Therapeutics, Inc. (US) 2021-06-16 EP disclosed
US-20200405866-A1 METHODS OF TREATING NAUSEA UTILIZING SEMI-SOLID DELIVERY VEHICLE COMPOSITIONS COMPRISING GRANISETRON HERON THERAPEUTICS, INC. 2020-12-31 US disclosed
US-20200323987-A1 TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS SONORAN BIOSCIENCES, INC. (US) 2020-10-15 US disclosed
EP-3700589-A1 TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS Sonoran Biosciences, Inc. (US) 2020-09-02 EP disclosed
EP-3424492-B1 SEMI-SOLID DELIVERY VECHICLE AND PHARMACEUTICAL COMPOSITIONS HERON THERAPEUTICS INC (US) 2020-05-27 EP disclosed
US-10357570-B2 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron HERON THERAPEUTICS, INC. (US) 2019-07-23 US disclosed
EP-3424492-A1 SEMI-SOLID DELIVERY VECHICLE AND PHARMACEUTICAL COMPOSITIONS Heron Therapeutics, Inc. (US) 2019-01-09 EP disclosed
EP-1280558-B1 SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS AP PHARMA INC (US) 2005-12-07 EP disclosed
US-6861068-B2 Pharmaceutical compositions using semi-solid delivery vehicle A.P. PHARMA, INC. (US) 2005-03-01 US disclosed
US-20050042194-A1 A polyorthoester and an excipient carrying antiemetic agents and anesthetics; topical or injectable forms; post operative or chemotherapy-induced emesis A.P. PHARMA, INC. (US) 2005-02-24 US disclosed
US-6790458-B2 MIXTURE OF POLYORTHOESTER AND EXCIPIENTS; SUSTAINED RELEASE AP PHARMA INC. 2004-09-14 US disclosed
US-20040156907-A1 Pharmaceutical compositions using semi-solid delivery vehicle HERON THERAPEUTICS, INC. (F/K/A A.P. PHARMA, INC.) 2004-08-12 US disclosed
US-20030212148-A1 Pharmaceutical compositions using semi-solid delivery vehicle AP PHARMA, INC. 2003-11-13 US disclosed
US-6613355-B2 Suitable for local delivery of the active agent, time-release agents A.P. PHARMA, INC. 2003-09-02 US disclosed
EP-1280558-A2 SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS Advanced Polymer Systems, Inc. (US) 2003-02-05 EP disclosed
US-20020037300-A1 Semi-solid delivery vehicle and pharmaceutical compositions HERON THERAPEUTICS, INC. (F/K/A A.P. PHARMA, INC.) 2002-03-28 US disclosed
WO-2001085139-A2 SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS ADVANCED POLYMER SYSTEMS, INC. (US) 2001-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037300-A1 Semi-solid delivery vehicle and pharmaceutical compositions LIPA, CEL, SORD MEN1 3661/4885KMT2A 3457/4885KDM4E 1899/4885
US-20030212148-A1 Pharmaceutical compositions using semi-solid delivery vehicle CEL, LIPA, SORD MEN1 3464/4885KMT2A 3736/4885KDM4E 2143/4885
US-20200323987-A1 TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS LCT, DLST, ALG1 MEN1 1203/4885KMT2A 4008/4885KDM4E 3690/4885
US-20200405866-A1 METHODS OF TREATING NAUSEA UTILIZING SEMI-SOLID DELIVERY VEHICLE COMPOSITIONS COMPRISING GRANISETRON LPXN, CRH, NTSR1 MEN1 1883/4885KMT2A 2578/4885KDM4E 2463/4885
US-20210252156-A1 METHODS OF TREATING NAUSEA UTILIZING SEMI-SOLID DELIVERY VEHICLE COMPOSITIONS COMPRISING GRANISETRON LPXN, CRH, NTSR1 MEN1 1883/4885KMT2A 2578/4885KDM4E 2463/4885
US-10357570-B2 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron LPXN, CRH, NTSR1 MEN1 1883/4885KMT2A 2578/4885KDM4E 2463/4885
US-20040156907-A1 Pharmaceutical compositions using semi-solid delivery vehicle CEL, LIPA, SORD MEN1 3464/4885KMT2A 3736/4885KDM4E 2143/4885
US-11173210-B2 Temperature-responsive degradable hydrogels LCT, DLST, ALG1 MEN1 1203/4885KMT2A 4008/4885KDM4E 3690/4885
US-20050042194-A1 A polyorthoester and an excipient carrying antiemetic agents and anesthetics; topical or injectable forms; post operative or chemotherapy-induced emesis PUF60, FAU, STOM MEN1 2664/4885KMT2A 3446/4885KDM4E 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.